Danish biotech executives are optimistic in Medwatch’s new state-of-the-market indicator. One biotech CEO believes that recent successes for a number of listed biotech companies have a great impact on the sector as a whole.
Novo Nordisk is currently conducting large-scale studies with new insulin drug Tresiba, as well as ground-breaking research within oral diabetes treatments. CSO Mads Krogsgaard Thomsen sheds light on the Danish pharma group’s expectations for the coming year.
Lundbeck CEO Ulf Wiinberg wants to at least double the company’s top line by 2020, and he says that it could even triple. The latter notion is definitely out of the question from the point of view of the stock market, says an industry analyst.
Antibodies are hot in the international pharmaceutical industry, and they might also hold the key to unlocking certain doors within brain disorders, according to Lundbeck, which is in the midst of creating a platform aimed at the field.
2013 has proved a lucrative year for Genmab so far, and the company's CEO believes in a good guidance for 2014 and a “quite profitable” short term future as well, especially due to milestone payments from collaborations with Lundbeck, among others.
Formal requirements for Bavarian Nordic’s small pox vaccine Imvanex have been met, but it is still uncertain whether or not the Danish government will stock up on the vaccine. A large-scale analysis sits on the table of the Danish Health and Medicines Authority, which could determine the fate of the drug.
Johnson & Johnson’s new diabetes drug Invokana could challenge Novo Nordisk’s Victoza in the short run, says an analyst. But it is a very different class of drug that the new product poses the biggest threat to.
The financial guidance for 2013 is boosted, as Genmab achieves its first milestone in the partnership with Janssen Pharmaceuticals concerning candidate drug daratumumab. The news has a positive effect on the share.
Some months after EU approval of Bavarian Nordic’s small pox vaccine, sales are beginning to take off in a number of countries and the company’s CEO expects Denmark to follow suit. But European sales are still modest compared with the US.
Danish biotech company Zealand Pharma could have a new blockbuster on its hands, assuming the recently initiated phase II study with candidate drug danegaptid yields strong data, says an analyst. CEO David Solomon believes the company is becoming a “significant player”.
Total turnover of medicine in Denmark has dropped between 2009 and 2012 in terms of value. Pharmacies and hospitals pull in different directions. Find out which five drugs have seen the biggest growth in sales.
Lundbeck is responsible for the marketing of a number of drugs, such as newly-approved schizophrenia drug Abilify Maintena, in Europe and sales related costs will make the next couple of years “a bit bleak”, says an analyst.
CEO of Bavarian Nordic, Anders Hedegaard, and Martin Bonde, Chairman of the industry organization Dansk Biotek, believe that Genmab’s possible inclusion in the OMXC20 CAP index will increase investor focus on other listed biotech companies.
Scientists from Yale University and University of Copenhagen have discovered a method for slowing down molecular biological processes in the liver that could lead to type 2 diabetes. Novo Nordisk’s head of diabetes research calls it an interesting area.
Current Chairman of the Board in Bavarian Nordic, Asger Aamund, will not be up for re-election, but is instead likely to be succeeded by a Dutch doctor. The company upholds its break even guidance for 2013.
Novo Nordisk, Leo Pharma, Lundbeck, Coloplast and R82 are among the representatives, as the Danish industry and the Crown Prince Couple woos Mexico in these days. The campaign is necessary in terms of export to the country and a trade agreement between the two countries has already been put in place.
Novo Nordisk has figured out a way to breed insulin-producing beta cells in a laboratory, which is a significant step towards a cure for type 1-diabetes. But for the pharmaceutical company the question remains; how great the business potential really is?
A newly started Masters degree in bio-entrepreneurship mixes a bio-scientific education with knowledge about financing and economy in a bid to encourage entrepreneurship and increase business opportunities for existing biotech companies.
From as early as 8th grade youngsters in the Danish town, Bagsværd, are able to attend a five-year long combined elementary and high-school education focused on biotechnology. The future biotechnicians, who are one year ahead of their peers, are urged to hone their powers of innovation.